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Background: Clinical trials (CT) represent an important treatment option for cancer patients. Unfortu-
nately, patients face challenges to enrolling in CTs, such as logistical barriers, poor CT understanding and
complex clinical regimens. Patient navigation is a strategy that may help to improve the delivery of CT
education and support services. We examined the feasibility and initial effect of one navigation strategy,
use of lay navigators.
Methods: A lay CT navigation intervention was evaluated in a prospective cohort study among 40 lung
and esophageal cancer patients. The intervention was delivered by a trained lay navigator who viewed a
17-min CT educational video with each patient, assessed and answered their questions about CT
participation and addressed reported barriers to care and trial participation.
Results: During this 12-month pilot project, 85% (95% CI: 72%e93%) of patients eligible for a therapeutic
CT consented to participate in the CT navigation intervention. Among navigated patients, CT under-
standing improved between pre- and post-test (means 3.54 and 4.40, respectively; p-value 0.004), and
95% (95% CI: 82%e98%) of navigated patients consented to participate in a CT. Navigated patients re-
ported being satisﬁed with patient navigation services and CT participation.
Conclusions: In this formative single-arm pilot project, initial evidence was found for the potential effect
of a lay navigation intervention on CT understanding and enrollment. A randomized controlled trial is
needed to examine the efﬁcacy of the intervention for improving CT education and enrollment.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
In 2015 cancer is expected to cause more than 589,000 deaths in
the US [1]. From a societal perspective, clinical trials (CT) are vital to
the discovery of efﬁcacious new cancer treatments to reduce the
burden of cancer. From the perspective of a cancer patient, CT
participation often represents access to clinically advanced treat-
ment options that are delivered with meticulous attention to the
treatment protocol. In the US, approximately 20% of cancer patientsCarolina, College of Nursing,
425, USA.
l).
access article under the CC BY liceare eligible for a cancer CT [2]. However only 3e5% of US cancer
patients actually participate in a CT [2]. Participation rates are even
lower among minority, rural, elderly and other underserved pop-
ulations [3e6]. Multi-level factors hinder CT enrollment, including
not being offered the opportunity to participate, lack of under-
standing about CTs, logistical issues such as cost, transportation,
complex clinical regimens, as well as systems issues such as lack of
physician knowledge about available CTs [7].
To date, most interventions to help patients overcome barriers
to CT participation have involved relatively brief educational in-
terventions. However, patient enrollment in CTs has not been
impacted by brief interventions such as standard CT educational
material [3e6] andmodiﬁed consent forms [8,9]. More tailored and
interactive educational interventions have yielded more promisingnse (http://creativecommons.org/licenses/by/4.0/).
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interactive computer-based CT educational formats, interactive
formats were associated with greater willingness to enroll in a CT
compared to standard CTeducational videos or brochures [10,11]. In
two studies that tested CT educational interventions tailored to
African Americans [12] or to common patient misperceptions about
CTs [11], patients reported greater willingness to participate in CTs
following the intervention. Interventions with the greatest poten-
tial to increase CT enrollment may be those that are interactive or
tailored to patient learning needs; but there are limited data testing
these types of interventions.
The National Cancer Institute (NCI) and the American Society of
Clinical Oncology (ASCO) recently summarized consensus recom-
mendations for research strategies that need to be tested for
improving patient participation in CTs [2]. In this report, patient
navigationwas recommended as a strategy that warrants testing. In
the clinical setting, patient navigation generally refers to strategies
that provide personal assistance to help patients overcome speciﬁc
educational, communication, and logistical barriers to treatment
and follow up medical care. The patient navigation approach could
be adapted and tested with the goal of overcoming the issues that
pose barriers to CT participation. Since patient navigation is an
individually tailored and interactive intervention, it has strong
potential as a strategy to improve personalized CT decision-making
and enrollment.
However, there are many operational deﬁnitions of navigation.
Applying the concept of navigation in a healthcare setting to
improve CT participation, two single arm trials have tested CT nurse
navigator interventions, one comprised of African American breast
cancer patients and the other of all types of cancer patients [13,14].
Both studies reported greater CT participation among navigated
patients compared to historical controls, providing evidence that
patient navigation may be an effective strategy for supporting pa-
tients in regard to CT participation [13,14]. Thus, a lay navigation
approach remains to be evaluated. The present study adds to the
small but growing evidence base by evaluating a lay navigation
intervention designed to provide patients with education about CTs
and assistance to overcome barriers to CT participation.
2. Methods
A prospective cohort study was conducted to evaluate the
feasibility and potential effect of a lay CT navigation intervention on
CT understanding and enrollment. The intervention design was
guided by the Chronic Care Model [15,16]. Speciﬁcally, for patients
who enrolled in the CT navigation intervention, we incorporated CT
decision support, linkage to community and health-system re-
sources, education about the CT treatment regimen for patients
who chose to participate in a CT to empower them in their role to
adhere to the therapeutic regimens, and clinical reminders.
2.1. Setting and participants
The study population was comprised of lung and esophageal
cancer patients potentially eligible for a therapeutic CT at one of
three NCI-afﬁliated cancer centers in South Carolina and Georgia.
To be eligible for this study, patients had to be age 18 or older,
planning to receive primary therapy at the cancer center, and be
potentially eligible for a therapeutic trial. No limitations were
placed on histological type/stage of cancer or cancer recurrence
status, as CTs take place across early to late stage cancers. The
intervention took place between September 2010 and September
2011. The study was approved by the institutional review boards at
each cancer center site, and all participants provided informed
consent prior to study participation.2.2. Clinical trial portfolio available at participating study sites
Prior to the start of the study, efforts were made to ensure that
trials were available across a wide range of lung and esophageal
cancer types and stages. Care was taken to ensure that trial avail-
ability reﬂected the patient population of the representative sites.
Across the overall trial portfolio, 47% of trials were single arm trials
(14% Phase 1 and 33% Phase 2) and 53% were Phase 3 randomized
controlled trials, with similar proportions of single arm and ran-
domized trials by study site. Of the 3 cancer center sites, one site
had 19 lung and 3 esophageal trials open, one site had 5 lung and 3
esophageal trials open, and one site had 12 lung and 2 esophageal
trials open. All study sites had 1e3 trials open for patients with
Stage 1B-Stage 4 non-small cell lung cancer, but only one site had a
trial open for stage 1A patients. All study sites had trials open for
limited and extensive small cell disease and esophageal cancer.
2.3. Intervention design
2.3.1. Choice of lay navigators to deliver the intervention
Lay navigators were chosen to deliver the navigation interven-
tion for several reasons. First, lay navigators who do not have
clinical responsibilities can focus solely on addressing non-clinical
barriers (sociocultural, economic, organization and individual)
that often disrupt CT recruitment and retention. Second, lay navi-
gators can be used as an affordable and sustainable resource to
extend the reach of clinical staff in providing patient education and
logistic and emotional support. Thus, the non-clinical lay naviga-
tors were non-clinical, lay staff who were recruited and trained
prior to study implementation. Each study site added one salaried
lay navigator who worked 20 h per week for this study. Lay navi-
gator salaries ranged from $30,000e$35,000 per year (prorated to a
20 h week), with educational level ranging from a licensed practical
nursing degree to a non-clinical master's degree. At each site, the
navigator was supervised by a CT nurse manager and supported by
a designated physician champion, whose role was to help ensure
the clinical team understood the navigator's support role and
responsibilities.
2.3.2. Navigator training
The lay navigators participated in a three-part training program
that included a 1.5-day didactic session, shadowing experiences, a 1
day practical session in which role playing was used to reinforce
mastery of navigation skills, and bi-weekly conference calls. Details
of the training have been previously reported in detail [17], but
brieﬂy the training protocol is described below:
For the didactic session, content included: (1) navigator's role
and responsibilities to facilitate CT education and provide practical
assistance to overcome barriers to care, with a focus on scope of
work boundaries (i.e. focus on CT education and support; not on CT
enrollment; no clinical advice or counseling), 2) clinical aspects of
lung and esophageal cancer, (2) overview of clinical trials, (3)
informed consent/conﬁdentiality, with an emphasis on core com-
ponents of informed consent, neutral presentation of CT option,
informed consent as a process, and patient's prerogative to decline
a CT or drop out at any time; (4) health literacy, (5) navigation
documentation/recordkeeping, and 6) time management/priority
setting. To further ensure that all lay navigators had a robust un-
derstanding about ethical practices in CT recruitment and their
expected roles, each navigator completed the University of Miami's
Basic Citi Course Training for Human Subjects Research [18] and the
Education Network to Advance Cancer Clinical Trials (ENAACT)
Foundation's Training Course on Enhancing Recruitment and
Retention Practices among the Medically Underserved [19].
For the shadowing experience, navigators shadowed key clinical
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included social workers, ﬁnancial counselors, patient educators and
lung/esophageal nurse coordinators and clinical trials coordinators.
Shadowing preceptors used a navigation shadowing check-off
sheet to help ensure that each navigator received exposure to the
same training content. Learning objectives focused on under-
standing the role of support personnel, identifying common bar-
riers to care, practicing active listening skills, and practicing referral
protocols.
For the 1-day practical training session in role-playing, the
entire multi-disciplinary team (physicians, nurses, trial co-
ordinators and navigators) took part in structured lessons in cul-
tural competencies. Video clips of common navigation scenarios
were created and used to provide the multi-disciplinary team
(including the navigator) with experiential lessons on the process
of interacting to resolve patient barriers via a team approach. Ob-
jectives focused on the roles of each multidisciplinary team mem-
ber, barriers to trial enrollment and retention, strategies navigators
can use to help patients overcome barriers, strategies required
within health system to overcome barriers, and relevant cultural
competencies. All participants then took part together in feedback
sessions and a performance checklist was used to evaluate the
navigator's mastery of navigation skills in cultural competencies.
The navigators also received ongoing support by participating in bi-
weekly calls with the project team that focused on real-time ex-
periences the navigator's negotiated daily.
2.3.3. Recruitment of patients for CT navigation intervention
Recruitment of patients for the CT navigation intervention was
designed to carefully follow the usual process of recruiting patients
for a CT. The usual CT recruitment process was that: 1) the study
coordinator pre-screened each patient for CT eligibility and
informed the provider if the patient was potentially eligible for a CT,
2) the provider further assessed the patient for CT eligibility in the
context of the patient's clinical condition and trial portfolio, and 3)
for patients who were CT candidates, the provider, accompanied by
the clinical team, met with the patient to inform them about their
treatment options, including the CT option.
Recruitment of patients for the patient navigation intervention
was built upon the process of CT recruitment. First, the study
coordinator pre-screened each patient to assess potential CT eligi-
bility and informed the provider if the patient was potentially
eligible for a CT. Next, the provider considered potential CT options
for the patient and informed the study coordinator if a CT option
was going to be presented to the patient. For patients who were
going to be presented with a CT option, the study coordinator
informed the patient about the CT navigation study and carried out
informed consent for the navigation study. The study coordinator
carried out the process of informed consent with the patient (rather
than the navigator) to avoid the potential for patients to feel obli-
gated to accept the navigator's help. If the patient agreed to
participate in the patient navigation intervention, the study coor-
dinator informed the navigator that the patient had accepted
navigation services. At that point, the provider, accompanied by the
clinical team and newly assigned navigator, met with the patient to
present themwith treatment options, which included the option to
participate in a CT.
2.3.4. CT navigation protocol
For patients who consented to the navigation study, the CT lay
navigation intervention started when the navigator ﬁrst partici-
pated in the patient's ﬁrst appointment with the oncologist and
others on the clinical team. Patients were offered a CToption during
this ﬁrst meeting. Information about the purpose of the CT, how the
patient ﬁt candidacy for the trial, what trial participation entailed,and patient rights/responsibilities in the trial were discussed.
Following this initial discussion, which included clinicians, the
CT lay navigator and patient watched a 17-min educational video
developed by the National Cancer Institute together [20]. The lay
navigator then discussed the CT with the patient, answered their
questions about the CT, or referred the question to the appropriate
clinical team member. The lay navigator also screened the patient
for potential barriers to care that could affect CT participation using
the Patient Navigation Research Program's Barrier Checklist [7]. In
some cases, patients completed informed consent to participate in
a CT immediately following their visit with the navigator and in
other cases they made their decision at a later point, often at the
time of their next clinic visit. From this point forward, the lay
navigator assisted the patient by 1) communicating reminders to
enhance compliance with the clinical trial protocol, 2) being a
liaison between the patient and clinical team about the patient's
care plan, 3) helping overcome logistical barriers to CT participa-
tion, and 4) providing emotional support, either directly or through
referrals. Informed consent for CT participation was completed by
the CT study coordinator at each site either during this initial
encounter or on a return visit, depending on patient preference.
2.4. Data sources and measures
Data sources included recruitment and participation logs for the
navigation intervention and CTs, interviewer-administered patient
surveys and medical records. A research team member adminis-
tered surveys to the patient prior to CT navigation and after the CT
decision to assess CT knowledge. If patients made a CT enrollment
decision on the day of CT presentation, the post-CT decision survey
was completed that day. If patients made a CT enrollment decision
at a follow-up appointment, the post-CT decision survey was
completed at the next visit. Patients completed a ﬁnal survey to
assess satisfaction with navigation services and CT participation
following treatment completion or withdrawal, whichever
occurred ﬁrst. The measures used in this report are described
below.
2.4.1. Socio-demographic and clinical characteristics
Race, ethnicity, gender, marital status, insurance status, and
education level were obtained by self-report using items adapted
from the Behavioral Risk Factor Surveillance System survey [21].
Age, tumor type, Eastern Cooperative Oncology Group (ECOG)
performance status (0 ¼ asymptomatic to 5 ¼ death) and cancer
recurrence status (yes, no) were obtained from the medical record.
Early stage cancer was deﬁned as stages I/II for non-small cell lung
cancer (NSCLC) and esophageal cancer and non-extensive for small
cell lung cancer (SCLC). Late stage cancer was deﬁned as stages III/
IV for NSCLC and esophageal cancer and extensive for SCLC.
2.4.2. Enrollment and retention outcomes
1) Enrollment rates in the CT lay navigation intervention and 2)
CT enrollment and retention rates were recorded on study
recruitment and participation logs. Reason codes were recorded for
trial-related factors (e.g. performance status, no matching trial),
provider factors (e.g. preferred standard of care, lack of time to
enroll patient) and patient factors (e.g. no desire for research,
transportation issues) for not participating in navigation.
Navigation enrollment was calculated as the percentage of pa-
tients who were eligible and consented to be navigated. CT
participation among navigated patients was calculated along the
trajectory of CT consent, enrollment and retention. Measures
included the percent of: 1) navigation enrollees who consented to a
CT; 2) navigation consenters who enrolled in a CT and 3) CT
enrollees who completed a CT. Because many of the patients in this
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of maintenance therapy to prevent cancer recurrence; CT comple-
tion was deﬁned as having completed at least the initial cycle of
therapy on a CT protocol (such as initial experimental surgery or
initial cycle of chemotherapy).2.4.3. CT knowledge
The “Seven-Item Knowledge Scale” [22] measured patient un-
derstanding of key CT factors such as knowledge of randomization,
clinical equipoise, experimental nature of research, andwhy CTs are
conducted. Response options on the scale are True, False and Don't
Know, which are transformed to correct vs. incorrect response.
Scores for the overall CT Knowledge Scale range from 0 to 7, with 7
being the highest knowledge score. This instrument has been used
in previous research studies reported in the literature, but has not
undergone formal psychometric evaluation.2.4.4. Patient satisfaction
The 5-item “Satisfaction with Clinical Trial Participation Scale”
[23] measured patient satisfaction with CT participation on a 5-
point Likert Scale ranging from Strongly Disagree to Strongly
Agree. A 10-item investigator-developed scale measured patient
satisfaction with CT navigation using 4-point Likert Scale formats.
Agreement with statements about satisfaction with the navigation
program was rated on a scale from “Very Dissatisﬁed to Very
Satisﬁed” and navigation quality on a scale from “Poor to Excellent.”2.5. Data analysis
Data were analyzed in SPSS Version 20. Participant character-
istics were summarized using frequency and percent distributions
or means (SD). For the CT Knowledge Scale, True, False and Don't
Know responses were recoded as correct or incorrect. Don't Know
and missing data were categorized as incorrect. The overall scale
ranged from 0 to 7, with 7 indicating the highest knowledge. For
individual items on the scale, pre-post percent differences in CT
knowledge were calculated as: [(post-test percent correct - pre-test
percent correct)/pre-test percent correct]. A McNemar Exact Test
was used to test the difference in the percent of correct responses at
pre and post-test for individual knowledge items. For the overall CT
knowledge scale, mean knowledge scores were calculated at both
pre and post test by averaging the percentage of correct scores for
all participants divided by the number of overall participants. Pre-
post differences in mean CT knowledge score were calculated as:
[(post-test mean score - pre-test mean score)/pre-test mean score].
To analyze change in overall CT knowledge between pre and post-
test, we report statistical signiﬁcance using both a Paired T-Test and
Wilcoxon Signed Rank Test. The Paired T-Test was used as the pri-
mary measure of change in overall scale scores because the prior
study that used the CT knowledge scale reported their results using
the Paired T-Test, and wewanted our results to be comparable with
other studies [22]. Additionally the T-test has been demonstrated to
be a robust statistical test when assumptions of normality are not
met [24]. Two-sided p-values of 0.05 or less were considered to be
statistically signiﬁcant. Satisfaction data were analyzed for indi-
vidual scale items as percent distributions of Likert Scale values.
Because the purpose of the study was to examine the process of
delivering the intervention in medical oncology clinics and to
collect preliminary data on the impact of the intervention, a target
sample sizewas not calculated based on formal hypotheses. Sample
size was based on the feasibility of recruitment, given the study
budget and timeframe for recruitment.3. Results
3.1. Navigation intervention recruitment process
Fig. 1 displays the results for the process of recruitment and
enrollment of patients into the clinical trial navigation intervention.
During the study period, 769 lung and esophageal cancer patients
were identiﬁed and of these, 23% (n ¼ 174) were formally screened
for a therapeutic CT. Reasons patients were not screened for a CT
were due to the lack of a CT matching the patient's cancer (n¼ 440;
74%), healthcare provider decision (n ¼ 61; 10%), diagnostic work-
up indicating no cancer (n ¼ 41; 7%), missed screening opportu-
nity (n ¼ 30; 5%), and other reasons (n ¼ 23; 4%). Only patients
formally screened for a CT were eligible for the navigation study.
Among the 174 patients screened for a CT, 27% (n ¼ 47) were
offered and eligible to participate in the navigation study, 8%
(n ¼ 14) were offered but became ineligible for navigation and 65%
(n ¼ 113) were not offered navigation. Reasons patients screened
for a CT were not offered or became ineligible for navigation were
due to failing CT eligibility or poor health status (n ¼ 39; 64%),
provider decision (n ¼ 18; 29%), treatment elsewhere (n ¼ 1; 2%),
being missed in clinic (n ¼ 1; 2%), CT refusal (n ¼ 1; 2%) and un-
known reasons (n ¼ 1; 2%). Among patients offered and eligible for
navigation, 85% (n ¼ 40; 95% CI: 72%e93%) enrolled in navigation.
Reasons for navigation refusal were no desire for navigation (n¼ 3;
43%), feeling overwhelmed by cancer (n ¼ 2; 29%), no desire to
participate in research (n¼ 1; 14%) and passive refusal (n¼ 1; 14%).3.2. Characteristics of study sample
Table 1 provides the characteristics of the 40 patients who
participated in the navigation intervention, along with comparison
statistics for those who were offered but did not participate in
navigation. The mean age of navigation participants was 63.1 years
(SD ¼ 9.56). Seventy three percent of participants (n ¼ 29) were
male. Seventy ﬁve percent of participants (n ¼ 30) were Caucasian
and 25.0% (n ¼ 10) were African American, with only 2.5% (n ¼ 1)
reporting Hispanic ethnicity. Ninety three percent (n ¼ 37) had
health insurance, 30.8% (n ¼ 13) had a college degree, 67.5%
(n ¼ 27) were married or living with a partner, and 66.7% (n ¼ 26)
were extremely/quite a bit conﬁdent completing medical forms.
Eighty ﬁve percent of participants (n ¼ 34) had non-small cell lung
cancer, 7.5% had small cell lung cancer (n ¼ 3), and 7.5% had
esophageal cancer (n ¼ 3). Similarly 85.0% of participants (n ¼ 34)
had late stage cancer and 15.0% (n ¼ 5) had cancer of unknown
stage. Forty percent of participants (n ¼ 16) received care from the
cancer center study site in Charleston (40.0%), 35.0% (n ¼ 14) from
Spartanburg, SC and 25.0% (n ¼ 10) from Savannah, GA.
A supplemental analysis was carried out to explore how navi-
gation program participants differed from those who were offered
but did not participate in the program. The characteristics of nav-
igation program participants (n ¼ 40) were compared with: 1)
those who agreed to navigation, but were unable to participate
(n ¼ 14), and, 2) those who refused navigation services (n ¼ 7).
Navigation participants were similar to those who agreed to navi-
gation, but were unable to participate in regard to race, ethnicity,
gender and insurance status. However navigation participants were
older and more likely to be unmarried and from the Charleston
study site. In a similar analysis that compared navigation partici-
pants with those who refused navigation, these two groups were
similar in regard to ethnicity, gender and insurance status. However
navigation participants were younger, less likely to be Caucasian
and more likely to be married and from the Charleston study site.
Clinic 
PaƟents 
(n=769)
23% Screened for 
a CT (n=174)
27% Oﬀered/Eligible 
NavigaƟon
(n=47)
85% Enrolled in 
NavigaƟon 
(n=40)
15% Refused 
NavigaƟon 
(n=7)
65% Not  Oﬀered 
NavigaƟon
(n=113)
77% Not Screened 
for a CT (n=595)
8% Oﬀered 
NavigaƟon/Became 
Ineligible
(n=14)
Fig. 1. Results for the process of recruitment and enrollment of patients into the clinical trial navigation intervention.
Table 1
Characteristics of Navigation Program Enrollees, Those who Agreed to Participate in Navigation but were Unable, and Those who Refused Navigation.
Characteristic Category a Participated in navigation study
(n ¼ 40)
Agreed to navigation, but unable to participate
(n ¼ 14) b
Refused navigation
(n ¼ 7)
N (%) N (%) N (%)
Age Mean (SD) 63.10 (SD ¼ 9.56) 58.86 (SD ¼ 8.99) 68.57 (SD ¼ 7.71)
Race Caucasian 30 (75.0) 11 (78.6) 7 (100)
African American 10 (25.0) 3 (21.4) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Ethnicity Non-Hispanic 39 (97.5) 13 (92.9) 7 (100)
Hispanic 1 (2.5) 1 (7.1) 0 (0)
Gender Male 29 (72.5) 10 (71.4) 5 (71.4)
Female 11 (27.5) 4 (28.6) 2 (28.6)
Insurance Status Uninsured 3 (7.5) 1 (7.1) 0 (0.0)
Insured 37 (92.5) 13 (92.9) 7 (100)
Marital Status Not Married 13 (32.5) 3 (21.4) 3 (42.9)
Married/living with
partner
27 (67.5) 11 (78.6) 4 (57.1)
Cancer Center Study
Site
Charleston 16 (40.0) 1 (7.1) 0 (0.0)
Savannah 10 (25.0) 8 (57.1) 3 (42.9)
Spartanburg 14 (35.0) 5 (35.7) 4 (57.1)
a Some categories do not sum to 100% due to rounding.
b “Agreed to Navigation, but Unable to Participate” was deﬁned as agreeing to participate in the navigation intervention, but being unable due to declining health or not
meeting ﬁnal eligibility criteria for a clinical trial.
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Among the 35 participants who completed pre and post-test
surveys, CT knowledge improved between pre- and post-test
(means 3.54 and 4.40, respectively; p-value ¼ 0.004 based on T-
Testing) (Table 2). Using a non-parametric testing approach (Wil-
coxon Signed Rank Test), a similar p-value of 0.005 was obtained.
The greatest knowledge gains were in understanding the concept of
randomization and that CTs are not only used when standard
treatments have not worked. The item with the lowest percentage
of correct baseline responses (n ¼ 5; 14% correct) was for not un-
derstanding that their doctor would not know which treatment
was better in a CT. No improvement for this item was observed at
post-test. For a similar item related to understanding that their
doctor would not be able to make sure they got the better treat-
ment in a CT, only 17% of patients (n¼ 6) answered correctly at pre-
test, with 23% answering correctly at post-test (n ¼ 8). This lack of
understanding that their doctor is unable to know or ensure thatthey receive the better treatment in a CT contrasts with the robust
improvement from 54% (n ¼ 19) at pre-test to 77% at post-test
(n ¼ 27) in understanding that treatment is decided by chance in
a CT.3.4. CT enrollment and retention outcomes
Fig. 2 provides CT enrollment and retention results for navigated
patients. Among the 40 patients who received CT navigation, 90%
(n ¼ 36) were presented with an opportunity to participate in a CT.
Reasons patients were not presented with a CT opportunity were
due to notmeeting ﬁnal CTeligibility criteria (75%) and death (25%).
Overall, 95% (n ¼ 34; 95% CI: 82%e98%) of patients given an
opportunity to participate in a CT did so, 76% (n ¼ 26; 95% CI: 60%e
88%) of CT consenters enrolled in a CT and 65% (n ¼ 17; 95% CI:
46%e81%) of CT enrollees completed a CT. Reasons that CT con-
senters did not enroll in a CT were poor ECOG performance status
(0 ¼ asymptomatic to 5 ¼ death) (n ¼ 4; 50%), progressive disease
Table 2
Comparison between pre-test and post-decision clinical trials knowledgea (n ¼ 35).
Item Correct at pre-test Correct at post-test Post-pre % diffb P-valuec
Frequency Percent Frequency Percent Percent
In a randomized trial the treatment you get is decided by chance (true) 19 54.3% 27 77.1% 42.0% 0.04
Clinical trials are only used when standard treatment have not worked (false) 17 48.6% 24 68.6% 41.2% 0.04
Clinical trials test treatments which nobody knows anything about (false) 23 65.7% 27 77.1% 17.4% 0.29
Randomized trials are the best way to ﬁnd out whether one treatment is better than another (true) 27 77.1% 30 85.7% 11.2% 0.45
Clinical trials are not appropriate for serious diseases like cancer (false) 27 77.1% 33 94.3% 22.3% 0.07
My doctor would know which treatment in a clinical trial was better (false) 5 14.3% 5 14.3% 0.0% 1.00
My doctor would make sure I got the better treatment in a clinical trial (false) 6 17.1% 8 22.9% 33.9% 0.63
Mean score (SD) for overall scale 3.54 (1.80) 4.40 (1.14) 24.3% 0.004
a The pre-post CT knowledge analysis includes 35 participants. Of 40 participants enrolled in navigation, 5 were lost to post-test survey follow up due to death (n ¼ 4) and
refusal (n ¼ 1).
b For individual scale items, percent difference scores were calculated as (post-test percent/pre-test percent)/pre-test percent. For the overall scale results, percent dif-
ference was calculated as (post-test mean/pre-test mean)/pre-test mean).
c A McNamar Exact Test was used to evaluate equality of correct response between pre and post-test for individual knowledge items. A Paired Sample T-Test was used to
evaluate the difference between overall mean pre and post test scores. For all analyses, statistical signiﬁcance was assessed using a 2-sided test at the .05 level.
Fig. 2. Results for the process of recruitment and enrollment of navigated patients into clinical trials.
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patients were often very sick and CT eligibility requires multi-steps
to assess eligibility, it was not uncommon for patients to complete
informed consent for a CT, but ultimately not meet ﬁnal CT eligi-
bility criteria. Reasons that CT enrollees did not complete a CT were
drug toxicities/adverse events (n ¼ 4; 44%), disease progression
(n ¼ 3; 33%) and death (n ¼ 2; 22%).
3.5. Patient satisfaction outcomes
Navigation participants who enrolled in a CT were asked about
satisfaction with patient navigation services and CT participation.
Among the 24 patients who completed the patient satisfaction
survey, all rated the quality of navigation services as good (n ¼ 8;
33%) or excellent (n ¼ 16; 67%) and were satisﬁed (n ¼ 10; 42%) orvery satisﬁed (n ¼ 14; 58%) with services. All participants agreed
(n ¼ 18; 75%) or strongly agreed (n ¼ 6; 25%) they were fully
informed about risks and beneﬁts of CT participation. Nearly all
participants either agreed (n ¼ 15; 63%) or strongly agreed (n ¼ 7;
29%) that they would recommend CT participation to a friend.
3.6. Limitations
Limitations to this study should be considered. First, the vast
majority of patients in the three cancer centers did not take part in
the navigation study, as only 40 of the 769 cancer center patients
participated in the navigation intervention. Thus, the patients
included in the navigation intervention do not represent a random
sample of clinic patients. The study cohort represents those pa-
tients for whom there was a matching CT, whose physician
K.B. Cartmell et al. / Contemporary Clinical Trials Communications 3 (2016) 86e9392determined that theywere appropriate candidates for a CTandwho
chose to participate in navigation. Second, the study lacked a
control group against which to compare intervention results. Third,
late stage cancer patients in our study may have been predisposed
to participate in research to optimize treatment outcomes. Fourth,
there was potential for selection bias if consent to the navigation
interventionwas correlated with CT consent. Thus, it is not possible
to assume causality between the navigation intervention and CT
enrollment outcomes. Essentially this study tested a new inter-
vention on a small scale that will need to be further tested in a
larger controlled trial.
4. Discussion
This study examined the feasibility and signs for a potential
effect of a lay navigation intervention to provide cancer patients
with CT education and support to overcome barriers to CT partici-
pation. The study demonstrated patient willingness to participate
in CT navigation, as only 15% of patients refused CT navigation.
Patients who refused navigation reported that they did not need
help navigating the clinical process. Two CT navigation studies
conducted among all types of cancer patients reported navigation
program refusal rates of 11% [14] and 44% [25]. Similar to our study,
the main reason for CT navigation refusal in these studies was that
navigationwas not needed. These ﬁndings provide evidence that CT
navigation is a service that most patients will accept, but that a
subset of patients without speciﬁc barriers to care will decline. The
major limiting factor for enrolling patients in CT navigation was
that most patients were not eligible or physically able to participate
in a CT. The second most common limiting factor for enrolling pa-
tients in CT navigationwas physician preference to offer standard of
care treatment, suggesting that some patients may have been
eligible for a CT, but were not offered the CT navigation interven-
tion. Provider decisions about offering a CT option to their patients
are often based on many factors such as knowledge of the available
trial portfolio in relation to their patient's condition, time con-
straints for enrolling and managing the patient on a CT and un-
derlying perceptions about CTs. Thus, it is important to take into
account that physician preference for standard of care therapy can
be driven by a number of underlying factors.
In this formative study, our recruitment process demonstrated
important issues to be addressed in a randomized trial. Based on
our study protocol, patients who were formally screened and
potentially eligible for a CT were eligible for CT navigation. How-
ever, a large proportion of clinic patients were not formally
screened for a CT, making them ineligible for the CT navigation
intervention. In a future study, systematic screening of all clinic
patients for a CT will be paramount to ensuring the optimal
recruitment yield within the clinic and to ensuring the generaliz-
ability of study ﬁndings.
In the present study, CT knowledge increased 24% between pre-
navigation and the CT decision. This magnitude of increase is
similar to RCTs that focused on increasing knowledge with a CT
nurse follow-call (25% knowledge increase) [26] and a total
disclosure consent form (24e46% increase) [9], and greater than
simply showing patients a CT educational video [27]. Variability in
patient understanding of survey items about randomization and
the doctor's role in this process were puzzling. Most patients un-
derstood that patients are randomly assigned to a treatment in a
randomized trial, but did not understand that their doctor is unable
to know or ensure they receive the better treatment in a CT. It is
possible that this ﬁndingmay be related to the fact that 47% of trials
available in the trial portfolio were not randomized. Patients may
have also had a different connotation when they encountered the
terms “randomized” vs. “clinical trial” in completing these surveyitems. It is also possible that patients may have difﬁculty
acknowledging their doctor has no inﬂuence in whether they
receive the optimal treatment in a CT. Further exploration of the
discordance of response across items may help to improve our
understanding of how patients process key CT concepts such as
randomization. Optimally patients need a complete understanding
about their CT option to make an informed CT decision. Thus, a key
focus for intervention research will be to ensure alignment of in-
struments used to measure CT knowledge with speciﬁc CT options
that patients are being offered and to incorporate a more targeted
educational approach that focuses on mastery of a key set of CT
knowledge items.
Among patients potentially eligible for a CT, our primary study
ﬁndings are that 85% (95% CI: 72%e93%) of patients were willing to
consent to the CT navigation intervention and of these, 95% (95% CI:
82%e98%) consented to a CT to the extent they were eligible and
physically able.
The 95% (95% CI: 82%e98%) CT consent in the current study
exceeds the 60% average CT consent reported in observational
studies of CT accrual [28e30]. This ﬁnding mirrors results from two
CT navigation interventions. In one of these studies conducted in
rural American Indians, a CT acceptance rate of 95% was reported
[31]. In a nurse navigation intervention that educated and sup-
ported cancer patients and providers about available CTs at an ac-
ademic medical center, 86% of patients accepted CT invitation [13].
When the results of the current study are considered across the
continuum of CT consent, enrollment and completion, only one
patient declined CT consent. Otherwise, the only reasons that pa-
tients failed to consent to, enroll in or complete a CT were due to CT
exclusion criteria or health issues that precluded CT participation.
These ﬁndings provide evidence that structured CT education plus
tangible support to communicate with the care team and overcome
logistical barriers can help most patients enroll in and complete a
CT.
5. Conclusions
The results of this pilot study suggest that patient navigation is
an intervention with potential to enhance both patient under-
standing and participation in cancer clinical trials. The study also
provides evidence that patients who receive CT navigation services
are satisﬁed with patient navigation and clinical trial services.
Based on promising results from this formative pilot work, a ran-
domized controlled trial is needed to examine the efﬁcacy of the
intervention on CT understanding and enrollment outcomes.
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